Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Zoetis ( (ZTS) ) has issued an update.
On May 21, 2025, Zoetis announced a dividend of $0.50 per share for the third quarter of 2025, payable on September 3, 2025, to shareholders recorded by July 18, 2025. This decision reflects the company’s ongoing commitment to returning value to its shareholders and may impact its financial positioning and stakeholder relations.
The most recent analyst rating on (ZTS) stock is a Buy with a $230.00 price target. To see the full list of analyst forecasts on Zoetis stock, see the ZTS Stock Forecast page.
Spark’s Take on ZTS Stock
According to Spark, TipRanks’ AI Analyst, ZTS is a Outperform.
Zoetis shows strong financial performance with impressive growth in revenue and margins, supported by robust earnings call insights. The high leverage on the balance sheet and valuation concerns slightly offset these strengths. Technical indicators suggest a stable trend, while the earnings call highlights strategic resilience and growth potential, contributing significantly to the overall positive outlook.
To see Spark’s full report on ZTS stock, click here.
More about Zoetis
Zoetis is the world’s leading animal health company, focused on advancing care for animals through a portfolio of medicines, vaccines, diagnostics, and technologies. With over 70 years of experience, Zoetis serves veterinarians, pet owners, and livestock producers in more than 100 countries. In 2024, the company generated $9.3 billion in revenue and employed approximately 13,800 people.
Average Trading Volume: 2,935,259
Technical Sentiment Signal: Sell
Current Market Cap: $72.99B
Find detailed analytics on ZTS stock on TipRanks’ Stock Analysis page.